Orphan Forecasts Meeting Xyrem Respiration Study Request By Year-End
This article was originally published in Pharmaceutical Approvals Monthly
Orphan Medical expects to fulfill FDA's requirement for an acute exposure study of Xyrem (sodium oxybate) in respiratory-compromised patients by the end of 2001, the company said in a July 3 conference call.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class